These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8625545

  • 21. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
    Dalakas MC.
    Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
    [Abstract] [Full Text] [Related]

  • 22. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, Glovsky M, Stiehm R, Stocks J, Rosenberg L, Shames RS, Corn B, Shearer WT, Bacot B, DiMaio M, Tonetta S, Adelman DC.
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [Abstract] [Full Text] [Related]

  • 23. Treatment of idiopathic inflammatory myopathies.
    Amato AA, Griggs RC.
    Curr Opin Neurol; 2003 Oct; 16(5):569-75. PubMed ID: 14501840
    [Abstract] [Full Text] [Related]

  • 24. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
    Dalakas MC.
    Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
    [Abstract] [Full Text] [Related]

  • 25. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].
    Cherin P.
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990
    [Abstract] [Full Text] [Related]

  • 26. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
    Göttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B.
    Eur J Dermatol; 2000 May; 10(1):29-35. PubMed ID: 10694294
    [Abstract] [Full Text] [Related]

  • 27. Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy.
    Megens-de Letter MA, Visser LH, van Doorn PA, Savelkoul HF.
    Eur Cytokine Netw; 1999 Dec; 10(4):471-8. PubMed ID: 10586113
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
    Pongratz D.
    J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
    [Abstract] [Full Text] [Related]

  • 29. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR.
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [Abstract] [Full Text] [Related]

  • 30. Inflammatory myopathies: management of steroid resistance.
    Dalakas MC.
    Curr Opin Neurol; 2011 Oct; 24(5):457-62. PubMed ID: 21799409
    [Abstract] [Full Text] [Related]

  • 31. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications.
    Efthimiou P.
    Semin Arthritis Rheum; 2006 Dec; 36(3):168-72. PubMed ID: 16970978
    [Abstract] [Full Text] [Related]

  • 32. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications.
    Greenberg SA.
    Neurology; 2007 Nov 20; 69(21):2008-19. PubMed ID: 17928577
    [Abstract] [Full Text] [Related]

  • 33. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin.
    Amemiya K, Semino-Mora C, Granger RP, Dalakas MC.
    Clin Immunol; 2000 Feb 20; 94(2):99-104. PubMed ID: 10637094
    [Abstract] [Full Text] [Related]

  • 34. Cytokines in idiopathic inflammatory myopathies.
    Salomonsson S, Lundberg IE.
    Autoimmunity; 2006 May 20; 39(3):177-90. PubMed ID: 16769651
    [Abstract] [Full Text] [Related]

  • 35. Potential therapeutic targets for idiopathic inflammatory myopathies.
    De Bleecker JL, Creus KK, De Paepe B.
    Drug News Perspect; 2006 Nov 20; 19(9):549-57. PubMed ID: 17220960
    [Abstract] [Full Text] [Related]

  • 36. Inflammatory myopathies [polymyositis, dermatomyositis, inclusion body myositis].
    Bertorini TE.
    Compr Ther; 1998 Oct 20; 24(10):494-502. PubMed ID: 9801848
    [Abstract] [Full Text] [Related]

  • 37. [Immunogenic myositis].
    Pongratz D.
    Dtsch Med Wochenschr; 2006 Feb 17; 131(7):330-6; quiz 337-8. PubMed ID: 16468103
    [Abstract] [Full Text] [Related]

  • 38. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy.
    Lockwood CM.
    Clin Exp Immunol; 1996 May 17; 104 Suppl 1():77-82. PubMed ID: 8625549
    [Abstract] [Full Text] [Related]

  • 39. High dose immunoglobulin therapy in a case of inclusion body myositis: clinical and immunologic aspects.
    Salvarani C, Boiardi L, Maldini MC, Mancini R, Rinaldi M, Macchioni P, Portioli I.
    J Rheumatol; 1993 Aug 17; 20(8):1455-6. PubMed ID: 8230050
    [No Abstract] [Full Text] [Related]

  • 40. Treatment of inflammatory myopathies.
    Mastaglia FL, Laing BA, Zilko P.
    Baillieres Clin Neurol; 1993 Nov 17; 2(3):717-40. PubMed ID: 8156149
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.